PreveCeutical to Develop Sol-Gel N2B Platform for Parkinson's Disease
PreveCeutical Medical Inc. (PRVCF) has announced a new program to develop their Nose to Brain (N2B) Sol-Gel platform for delivering Dopamine and L-Dopa directly to the brain for Parkinson's disease treatment. The technology is designed to bypass the Blood Brain Barrier (BBB), which could potentially improve drug bioavailability while reducing side effects associated with current delivery methods.
The company expects this approach to enhance safety and effectiveness by avoiding systemic exposure and requiring lower therapeutic doses through direct brain targeting. The N2B platform's ability to bypass other body compartments could lead to reduced drug dosages and improved patient compliance.
PreveCeutical plans to demonstrate proof of concept in preclinical models before seeking partnerships with organizations specializing in Parkinson's disease.
PreveCeutical Medical Inc. (PRVCF) ha annunciato un nuovo programma per sviluppare la loro piattaforma Sol-Gel Nose to Brain (N2B) per la somministrazione diretta di Dopamina e L-Dopa al cervello per il trattamento della malattia di Parkinson. La tecnologia è progettata per oltrepassare la barriera emato-encefalica (BBB), il che potrebbe migliorare la biodisponibilità del farmaco riducendo al contempo gli effetti collaterali associati ai metodi di somministrazione attuali.
L'azienda si aspetta che questo approccio migliori la sicurezza e l'efficacia evitando l'esposizione sistemica e richiedendo dosi terapeutiche inferiori attraverso il targeting diretto del cervello. La capacità della piattaforma N2B di bypassare altre compartimenti corporei potrebbe portare a dosaggi ridotti e a una migliore aderenza da parte dei pazienti.
PreveCeutical prevede di dimostrare la prova di concetto in modelli preclinici prima di cercare partnership con organizzazioni specializzate nella malattia di Parkinson.
PreveCeutical Medical Inc. (PRVCF) ha anunciado un nuevo programa para desarrollar su plataforma Sol-Gel Nose to Brain (N2B) para la entrega de Dopamina y L-Dopa directamente al cerebro para el tratamiento de la enfermedad de Parkinson. La tecnología está diseñada para eludir la Barrera Hematoencefálica (BBB), lo que podría mejorar la biodisponibilidad del fármaco mientras reduce los efectos secundarios asociados con los métodos de entrega actuales.
La empresa espera que este enfoque mejore la seguridad y la eficacia al evitar la exposición sistémica y requerir dosis terapéuticas más bajas a través de la orientación directa al cerebro. La capacidad de la plataforma N2B para eludir otros compartimentos del cuerpo podría llevar a dosis reducidas y a una mejor adherencia por parte de los pacientes.
PreveCeutical planea demostrar la prueba de concepto en modelos preclínicos antes de buscar asociaciones con organizaciones especializadas en la enfermedad de Parkinson.
PreveCeutical Medical Inc. (PRVCF)는 도파민과 L-Dopa를 뇌에 직접 전달하기 위한 Nose to Brain (N2B) Sol-Gel 플랫폼을 개발하는 새로운 프로그램을 발표했습니다. 이는 파킨슨병 치료를 위한 기술로, 혈액-뇌 장벽(BBB)을 우회하도록 설계되어 현재 전달 방식에 따른 부작용을 줄이면서 약물의 생체이용률을 개선할 수 있습니다.
회사는 이러한 접근 방식이 전신 노출을 피하고 뇌를 직접 표적하여 더 낮은 치료 용량을 요구함으로써 안전성과 효과성을 향상시킬 것으로 기대하고 있습니다. N2B 플랫폼이 다른 신체 부분을 우회할 수 있는 능력은 약물의 용량을 줄이고 환자의 순응도를 향상시킬 수 있습니다.
PreveCeutical은 파킨슨병 전문 조직과의 파트너십을 찾기 전에 전임상 모델에서 개념 증명을 보여줄 계획입니다.
PreveCeutical Medical Inc. (PRVCF) a annoncé un nouveau programme pour développer leur plateforme Sol-Gel Nose to Brain (N2B) afin de délivrer de la Dopamine et de la L-Dopa directement au cerveau pour le traitement de la maladie de Parkinson. La technologie est conçue pour contourner la Barrière Hémato-encéphalique (BBB), ce qui pourrait potentiellement améliorer la biodisponibilité du médicament tout en réduisant les effets secondaires associés aux méthodes de délivrance actuelles.
L'entreprise s'attend à ce que cette approche améliore la sécurité et l'efficacité en évitant l'exposition systémique et en nécessitant des doses thérapeutiques plus faibles grâce à un ciblage direct du cerveau. La capacité de la plateforme N2B à contourner d'autres compartiments corporels pourrait conduire à une réduction des dosages des médicaments et à une meilleure adhésion des patients.
PreveCeutical prévoit de démontrer la preuve de concept dans des modèles précliniques avant de chercher des partenariats avec des organisations spécialisées dans la maladie de Parkinson.
PreveCeutical Medical Inc. (PRVCF) hat ein neues Programm zur Entwicklung ihrer Nose to Brain (N2B) Sol-Gel-Plattform zur direkten Abgabe von Dopamin und L-Dopa an das Gehirn für die Behandlung von Parkinson angekündigt. Die Technologie zielt darauf ab, die Blut-Hirn-Schranke (BBB) zu umgehen, was potenziell die Bioverfügbarkeit des Medikaments verbessern und gleichzeitig die mit aktuellen Verabreichungsmethoden verbundenen Nebenwirkungen verringern könnte.
Das Unternehmen erwartet, dass dieser Ansatz die Sicherheit und Wirksamkeit verbessert, indem er systemische Exposition vermeidet und niedrigere therapeutische Dosen durch die direkte Ansprache des Gehirns erforderlich sind. Die Fähigkeit der N2B-Plattform, andere Körperkompartimente zu umgehen, könnte zu einer Verringerung der Medikamentendosen und einer verbesserten Patientencompliance führen.
PreveCeutical plant, den Konzeptnachweis in präklinischen Modellen zu erbringen, bevor Partnerschaften mit Organisationen gesucht werden, die auf Parkinson spezialisiert sind.
- Innovative drug delivery system bypassing the Blood Brain Barrier
- Potential for reduced drug dosages and fewer side effects
- Technology could improve drug bioavailability and patient compliance
- Program is in early stages with no clinical validation yet
- Success depends on future partnerships for commercialization
- No timeline provided for development milestones
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces a program aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Nose to Brain (N2B) Sol-Gel platform delivery technology.
PreveCeutical's program is aiming to deliver Dopamine and/or its precursor L-Dopa directly to the brain using their Sol-Gel N2B delivery technology. Extensive scientific research supports the provision of a steady, sustained dose of the neurotransmitter, or its precursor, to mitigate Parkinson's disease symptoms even at an advanced stage. PreveCeutical anticipates the safety and the effectiveness of the approach to be improved through avoidance of side effects stemming from systemic exposure, and a need for lower therapeutic doses due to direct brain targeting. Further information will be provided as the program is advanced.
The Sol-Gel N2B delivery platform is designed to altogether bypass the Blood Brain Barrier (BBB), potentially improving drug bioavailability while reducing dose-related side effects associated with current drug delivery methods.
The versatility of the N2B platform delivery system paves the way for delivering therapeutics to the brain without encountering the BBB and bypassing all other body compartments; these collective attributes have the potential to reduce drug dosages and side effects, improving patient compliance and clinical outcomes.
Chairman and CEO Stephen Van Deventer commented.
"PreveCeutical's business model aims to develop cost-effective, preventive and curative therapies for patients globally. Once the program has successfully infused Dopamine and/or L-Dopa into the Sol-Gel platform, with PoC demonstrated in a preclinical model, we will explore partnerships with corporations and/or organizations who specialize in the field of Parkinson's disease".
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs. For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedar.com. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/239823
FAQ
What is PreveCeutical's (PRVCF) new Sol-Gel N2B platform designed to treat?
How does PreveCeutical's (PRVCF) Sol-Gel N2B technology work for Parkinson's treatment?
What are the potential advantages of PRVCF's Sol-Gel N2B platform over current treatments?
What is PreveCeutical's (PRVCF) next step for the Sol-Gel N2B Parkinson's program?
